The FDA Vaccines and Related Biological Products Advisory Committee holds a meeting to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in Biologics License Application STN 125869/0 for the prevention of influenza disease caused by influenza virus subtypes A and B represented in the vaccine, in persons 50 years of age and older.
Source link
LIVE NOW: FDA Vaccines Advisory Committee Meets on Moderna’s mRNA Influenza Vaccine MFLUSIVA
Previous article![]( "FDA Panel Considers a First-Of-Its-Kind Flu Vaccine Using MRNA Technology")
Next article![]( "Bank of England leaves interest rates on hold and lowers inflation forecast amid Middle East ‘uncertainty’ – business live | Business")
